Download PDF
Thromb Haemost 2018; 118(04): 688-699
DOI: 10.1055/s-0038-1637734
Coagulation and Fibrinolysis
Schattauer GmbH Stuttgart

Human Dendritic Cells Synergistically Activated by FVIII Plus LPS Induce Activation of Autologous CD4+ T Cells

Lilija Miller
1   Section 3/1 “Product Testing of Biomedicines,” Paul-Ehrlich-Institut, Langen, Germany
,
Eva Ringler
1   Section 3/1 “Product Testing of Biomedicines,” Paul-Ehrlich-Institut, Langen, Germany
,
Klaus Maximilian Kistner
1   Section 3/1 “Product Testing of Biomedicines,” Paul-Ehrlich-Institut, Langen, Germany
,
Zoe Waibler
1   Section 3/1 “Product Testing of Biomedicines,” Paul-Ehrlich-Institut, Langen, Germany
,
on behalf of the ABIRISK Consortium › Author Affiliations Funding Partially, the research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no [115303], resources of which are composed of financial contribution from the European Union's Seventh Framework Program (FP7/2007–2013) and EFPIA companies' in kind contribution.
Further Information

Publication History

13 June 2017

30 January 2018

Publication Date:
19 March 2018 (online)

Also available at
    Permissions and Reprints

Abstract

The most severe side effect in haemophilia A (HA) treatment is the development of anti-factor VIII antibodies, also called inhibitors. Why inhibitors develop in a proportion of treated HA patients and how this can be prevented remains largely unanswered. Among numerous theories, the presence of immunological danger signals, associated with events such as surgery or infection, has been proposed to play a role. In this study, we demonstrate that human dendritic cells (DC) synergistically activated by a combination of factor VIII (FVIII) concentrate plus the bacterial danger signal lipopolysaccharide (LPS) induce a significantly stronger activation of autologous CD4+ T cells than DC pretreated with FVIII or LPS alone. The observed T cell activation is dependent on antigen processing, presentation on MHC class II molecules and costimulation via CD86. Of note, FVIII plus LPS pretreated DC predominantly induce the activation of memory T cells and a minor proportion of naive T cells. Collectively, our data support a model in which immunological danger signals plus FVIII concentrates synergistically increase human CD4+ T cell responses to FVIII protein.

Keywords

anti-FVIII immune response - lipopolysaccharide - T cells - danger signal - inhibitors

Authors' Contributions

L.M. performed experiments, collected, analysed and interpreted the data, generated figures and wrote the article; E.R. and K.M.K. performed experiments; Z.W. designed experiments, interpreted the data and wrote the article.


Supplementary Material

 

  • References

  • 1 Graw J, Brackmann H-H, Oldenburg J, Schneppenheim R, Spannagl M, Schwaab R. Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet 2005; 6 (06) 488-501
    CrossrefPubMedGoogle Scholar
  • 2 Gouw SC, van den Berg HM, Oldenburg J. , et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012; 119 (12) 2922-2934
    CrossrefPubMedGoogle Scholar
  • 3 Oldenburg J, Schröder J, Brackmann HH, Müller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol 2004; 41 (01) (Suppl. 01) 82-88
    CrossrefPubMedGoogle Scholar
  • 4 Eckhardt CL, van Velzen AS, Peters M. , et al; INSIGHT Study Group. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 2013; 122 (11) 1954-1962
    CrossrefPubMedGoogle Scholar
  • 5 Hu G-L, Okita DK, Diethelm-Okita BM, Conti-Fine BM. Recognition of coagulation factor VIII by CD4+ T cells of healthy humans. J Thromb Haemost 2003; 1 (10) 2159-2166
    CrossrefPubMedGoogle Scholar
  • 6 Whelan SFJ, Hofbauer CJ, Horling FM. , et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 2013; 121 (06) 1039-1048
    CrossrefPubMedGoogle Scholar
  • 7 Algiman M, Dietrich G, Nydegger UE, Boieldieu D, Sultan Y, Kazatchkine MD. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci U S A 1992; 89 (09) 3795-3799
    CrossrefPubMedGoogle Scholar
  • 8 Miller L, Weissmüller S, Ringler E. , et al; ABIRISK consortium. Danger signal-dependent activation of human dendritic cells by plasma-derived factor VIII products. Thromb Haemost 2015; 114 (02) 268-276
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109 (11) 4648-4654
    CrossrefPubMedGoogle Scholar
  • 10 Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010; 16 (02) 256-262
    CrossrefPubMedGoogle Scholar
  • 11 Gouw SC, van den Berg HM. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost 2009; 35 (08) 723-734
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Yoshimori T, Yamamoto A, Moriyama Y, Futai M, Tashiro Y. Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem 1991; 266 (26) 17707-17712
    PubMedGoogle Scholar
  • 13 Mayer S, Laumer M, Mackensen A, Andreesen R, Krause SW. Analysis of the immune response against tetanus toxoid: enumeration of specific T helper cells by the Elispot assay. Immunobiology 2002; 205 (03) 282-289
    CrossrefPubMedGoogle Scholar
  • 14 Pfistershammer K, Stöckl J, Siekmann J, Turecek PL, Schwarz HP, Reipert BM. Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells. Thromb Haemost 2006; 96 (03) 309-316
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Danke NA, Koelle DM, Yee C, Beheray S, Kwok WW. Autoreactive T cells in healthy individuals. J Immunol 2004; 172 (10) 5967-5972
    CrossrefPubMedGoogle Scholar
  • 16 Koehler NKU, Genain CP, Giesser B, Hauser SL. The human T cell response to myelin oligodendrocyte glycoprotein: a multiple sclerosis family-based study. J Immunol 2002; 168 (11) 5920-5927
    CrossrefPubMedGoogle Scholar
  • 17 Reding MT, Wu H, Krampf M. , et al. Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 2000; 84 (04) 643-652
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Moreau A, Lacroix-Desmazes S, Stieltjes N. , et al. Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG. Blood 2000; 95 (11) 3435-3441
    CrossrefPubMedGoogle Scholar
  • 19 Nádházi Z, Takáts A, Offenmüller K, Bertók L. Plasma endotoxin level of healthy donors. Acta Microbiol Immunol Hung 2002; 49 (01) 151-157
    CrossrefPubMedGoogle Scholar
  • 20 Bischoff SC, Barbara G, Buurman W. , et al. Intestinal permeability--a new target for disease prevention and therapy. BMC Gastroenterol 2014; 14: 189
    CrossrefPubMedGoogle Scholar